Clinical data | |
---|---|
Trade names | Tiapridal |
Routes of administration | Oral (tablets), IM, IV |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ~75% (oral) (Tmax = 1 hour) |
Protein binding | Negligible |
Elimination half-life | 2.9–3.6 hours |
Excretion | Urine (70% as unchanged tiapride) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.051.717 |
Chemical and physical data | |
Formula | C15H24N2O4S |
Molar mass | 328.43 g·mol−1 |
3D model (JSmol) | |
| |
(verify) |
Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain. It is used to treat a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly.[2] A derivative of benzamide, tiapride is chemically and functionally similar to other benzamide antipsychotics such as sulpiride and amisulpride known for their dopamine antagonist effects.